Published in Eur J Cancer on February 20, 2017
Dendritic cells and the control of immunity. Nature (1998) 56.54
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 10.73
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2012) 10.47
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature (2009) 9.74
The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity (2008) 7.60
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science (2012) 7.08
STING is a direct innate immune sensor of cyclic di-GMP. Nature (2011) 6.44
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A (2009) 4.46
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Nucleic acid recognition by the innate immune system. Annu Rev Immunol (2011) 4.00
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun (2010) 3.89
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol (2008) 3.65
The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep (2013) 3.08
Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell (2013) 2.97
Immune sensing of DNA. Immunity (2013) 2.96
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2013) 2.68
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity (2014) 2.28
Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev (2007) 2.22
Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol (2011) 2.19
STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell (2013) 2.18
The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol (2012) 2.11
Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol (2012) 2.00
Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol (2013) 1.85
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep (1986) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A (2013) 1.41
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med (2015) 1.33
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem (2012) 1.33
The interferon response to intracellular DNA: why so many receptors? Immunobiology (2013) 1.30
STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res (2014) 1.24
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Dendritic cells in cancer immunotherapy. Eur J Immunol (2010) 1.19
Inflammation-driven carcinogenesis is mediated through STING. Nat Commun (2014) 1.19
Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1. J Virol (2014) 1.16
DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science (2015) 1.16
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res (2012) 1.15
Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol (2013) 1.13
STING: infection, inflammation and cancer. Nat Rev Immunol (2015) 1.12
Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol (2013) 1.12
Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One (2013) 1.11
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res (2014) 1.04
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. Cell Rep (2015) 1.03
Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol (2014) 1.02
Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr Opin Immunol (2014) 1.01
Diverse roles of STING-dependent signaling on the development of cancer. Oncogene (2015) 0.98
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol (2016) 0.98
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A (2015) 0.97
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology (2015) 0.94
RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res (2014) 0.94
T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication. PLoS One (2014) 0.92
STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol (2014) 0.91
The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells. Immunity (2016) 0.90
Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol (2014) 0.89
Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol (1989) 0.89
Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines (2013) 0.89
Immunomodulatory actions of xanthenone anticancer agents. BioDrugs (1997) 0.89
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol (2006) 0.87
TH9 cells in anti-tumor immunity. Semin Immunopathol (2016) 0.84
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother (2015) 0.84
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res (2016) 0.83
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res (2016) 0.82
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res (2015) 0.81
Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol (2014) 0.79
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. Sci Rep (2016) 0.78
Stimulator of interferon genes (STING): A "new chapter" in virus-associated cancer research. Lessons from wild-derived mouse models of innate immunity. Cytokine Growth Factor Rev (2016) 0.76